Trial Profile
Phase 1 study of AD114 for the treatment of Idiopathic pulmonary fibrosis
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2017
Price :
$35
*
At a glance
- Drugs AD 114 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- 09 Jan 2017 According to an AdAlta media release, the company anticipates to initiate this study by early 2018.
- 03 Aug 2016 New trial record